- Home
- PCRX vs NKTR Comparison
PCRX vs NKTR Comparison
Compare PCRX & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- NKTR
- Stock Information
- Founded
- PCRX 2006
- NKTR 1990
- Country
- PCRX United States
- NKTR United States
- Employees
- PCRX N/A
- NKTR N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- NKTR Health Care
- Exchange
- PCRX Nasdaq
- NKTR Nasdaq
- Market Cap
- PCRX 1.2B
- NKTR 1.2B
- IPO Year
- PCRX 2011
- NKTR 1994
- Fundamental
- Price
- PCRX $21.85
- NKTR $54.26
- Analyst Decision
- PCRX Buy
- NKTR Strong Buy
- Analyst Count
- PCRX 5
- NKTR 6
- Target Price
- PCRX $32.40
- NKTR $91.67
- AVG Volume (30 Days)
- PCRX 577.9K
- NKTR 877.1K
- Earning Date
- PCRX 11-06-2025
- NKTR 11-06-2025
- Dividend Yield
- PCRX N/A
- NKTR N/A
- EPS Growth
- PCRX N/A
- NKTR N/A
- EPS
- PCRX N/A
- NKTR N/A
- Revenue
- PCRX $705,848,000.00
- NKTR $74,934,000.00
- Revenue This Year
- PCRX $7.27
- NKTR N/A
- Revenue Next Year
- PCRX $10.18
- NKTR N/A
- P/E Ratio
- PCRX N/A
- NKTR N/A
- Revenue Growth
- PCRX 2.25
- NKTR N/A
- 52 Week Low
- PCRX $16.00
- NKTR $6.48
- 52 Week High
- PCRX $27.64
- NKTR $66.92
- Technical
- Relative Strength Index (RSI)
- PCRX 41.81
- NKTR 44.42
- Support Level
- PCRX $21.20
- NKTR $59.01
- Resistance Level
- PCRX $22.74
- NKTR $66.92
- Average True Range (ATR)
- PCRX 0.96
- NKTR 4.74
- MACD
- PCRX 0.14
- NKTR -1.14
- Stochastic Oscillator
- PCRX 59.08
- NKTR 2.69
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.